Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.59 USD | +3.90% | +2.49% | -9.40% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.40% | 491M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+2.18% | 22.67B | |
-10.09% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $21, Maintains Outperform Rating